Eli Lilly (LLY) Q2 2024 Earnings
LLY·Reported August 8, 2024·Before market open
Eli Lilly reported Q2 2024 revenue of $11.3B, beat analyst consensus of $10.0B by $1.3B. Diluted EPS came in at $3.92, beat the $2.60 consensus by $1.32. Eli Lilly reports across 4 business segments, led by Cardiometabolic Health, Oncology, and Immunology.
Revenue
$11.3Bbeat by $1.3B
Consensus: $10.0BDiluted EPS
$3.92beat by $1.32
Consensus: $2.60
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about Eli Lilly's Q2 2024 earnings report.
Eli Lilly (LLY) reported Q2 2024 earnings on August 8, 2024 before market open.
Eli Lilly reported revenue of $11.3B and diluted EPS of $3.92 for Q2 2024.
Revenue beat the consensus estimate of $10.0B by $1.3B. EPS beat the consensus estimate of $2.60 by $1.32.
You can read the 10-Q periodic report (0000059478-24-000187) directly on SEC EDGAR. The filing index links above go to sec.gov.